Table of Contents Table of Contents
Previous Page  300 / 812 Next Page
Information
Show Menu
Previous Page 300 / 812 Next Page
Page Background

S296

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348

Conclusions

1. CRP, a potential inflammatory biomarker in

schizophrenia, is related to depression severity. Homocysteine,

representing an oxidative stress, is related to positive, negative,

cognitive and depressive symptoms severity, and worse function-

ing. 2. Patients with schizophrenia have lower HDL–related to neg-

ative and cognitive symptoms severity and worse functioning–and

insulin resistance – related to worse cognition –.

Table 1

Table 2

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

References

[1] Kirkpatrick B, Miller B, García-Rizo C, Fernandez-Egea E.

Schizophrenia: a systemic disorder. Clin Schizophr Relat Psy-

choses 2014;8(2):73–9.

[2] Miller BJ, Buckley P, et al. Meta-analysis of cytokine alterations

in schizophrenia: clinical status and antipsychotic effects. Biol

Psychiatry 2011;70(7).

http://dx.doi.org/10.1016/j.eurpsy.2016.01.635

EW518

Clinical and functional response to

paliperidone palmitate in early

schizophrenia–A retrospective

observational study in newly

diagnosed patients treated over a

12-month period

L. Hargarte

r 1 ,

, P . B

ergmans

2 , P. C

herubin

3 , A.

Schreiner

1

1

Janssen Cilag Germany, Medical Affairs EMEA, Neuss, Germany

2

Janssen Cilag Netherlands, Biostatistics, Tilburg, Netherlands

3

Janssen Cilag France, Medical Affairs EMEA, Issy-Lès-Moulineaux,

France

Corresponding author.

Introduction

Data on clinical outcomes with long-acting antipsy-

chotic treatment in young, newly diagnosed patients with

schizophrenia is sparse.

Objectives

To explore hospitalization, drug utilization and

clinical outcomes from medical records of newly diagnosed

schizophrenia patients during first 12 months of treatment with

once-monthly paliperidone palmitate (PP).

Methods

International, multicenter, retrospective, observational

study. Outcomes presented: baseline (BL) characteristics and

demographics, clinically relevant improvements in disease sever-

ity (ie

20% decrease in PANSS or BPRS total score or CGI-S

Change

≥−

2 or CGI-C

3, with no score showing worsening) and

clinically relevant functional improvement (i.e. change in PSP total

score

+7 points or change in GAF total score

+20 points, with

no score showing worsening) from BL to last-observation-carried-

forward endpoint (LOCF-EP) within 12-month documentation

period, mean mode PP dose and adverse drug reactions.

Results

Eighty-four patients analyzed: 69% male, mean age at

initiation of PP was 24.1 (SD2.7) years, mean BL weight was 78.7

(SD16.0) kg and 80.0 (SD14.7) kg at LOCF-EP, with a mean change

of 1.2 (SD3.9) kg; mean time from first psychotic episode to initi-

ation of PP was 5.5 (SD3.3) months. At LOCF-EP 86.6% achieved a

clinically relevant improvement (71/84, Kaplan-Meiermedian time

from initiation of PP: 52.4 days). 63.4% achieved a clinically relevant

functional improvement (52/84, Kaplan-Meier median time from

initiation of PP: 53.1 days). PP mean mode maintenance dose was

96.4 (SD19.8) mg. ADRs reported in

5% of patients were weight

increase 9.1% and hyperprolactinemia 5.7%.

Conclusions

Treatment with once-monthly PP was well tolerated

and associated with clinically relevant improvements in disease

severity and functioning in young, newly diagnosed schizophrenia

patients.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.636

EW519

Early schizophrenia patients treated

with once-monthly paliperidone

palmitate over a 12-month period - a

retrospective observational study

L. Hargarter

1 ,

, P . B

ergmans

2 , P. C

herubin

3 , A. S

chreiner

1

1

Janssen Cilag Germany, Medical Affairs EMEA, Neuss, Germany

2

Janssen Cilag Netherlands, Biostatistics, Tilburg, Netherlands

3

Janssen Cilag France, Medical Affairs EMEA, Issy-Lès-Moulineaux,

France

Corresponding author.

Introduction

Little is known about patient characteristics and

rehospitalization in newly diagnosed patients with schizophrenia

treated with long-acting antipsychotics.

Objectives

To retrospectively explore hospitalizations, drug uti-

lization and clinical outcomes from medical records of young,

newly diagnosed schizophrenia patients during the first 12

months of treatment with once-monthly paliperidone palmitate

(PP).

Methods

International, multicenter, retrospective, observational

study. Outcomes presented are patient characteristics, reason for

PP initiation and hospitalization data.

Results

Eighty-four patients were analyzed: mean age (years)

at first psychotic episode was 23.8 (SD2.6), 23.9 (SD2.6) at first

antipsychotic treatment and 24.1 (SD2.7, range 19-29) at PP initia-

tion. Time between first antipsychotic treatment and PP initiation

was 4.8 (SD: 3.4, range: 0-12) months. At PP initiation, 42.9% of

patients were in hospital, primarily for the management of the first

episode/relapse (97.2%). Reason for PP initiation was: LAT favored

over oral treatment for relapse prevention (56%), partial/non adher-

ence with previous oral medication (20.0%), convenience (15.5%)

or limited access to health care systems (2.4%). Mean time (days)

between admission and initiation of PP, and between initiation

of PP and discharge from hospital was 28.8 (SD23.0) and 23.2

(SD24.5), respectively. 96.4% of patients were not hospitalized dur-

ing the 12-month PP treatment period. 3/84 patients (3.6%) had

a single hospitalization of 15.7 (SD: 8.1) days for management of

episode/relapse.